Phospholipid Second Messenger System: PLC/DAG/IP3/PKC
Phospholipid signalling (membrane-derived second messengers; canonical pathway: GPCR (Gq) or RTK (EGFR/PDGFR/TrkB) → PLC (phospholipase C): PLC-β (Gq/Gβγ-activated; 4 subtypes: β1–4); PLC-γ1/2 (RTK/BCR/TCR; SH2 domain-mediated; Tyr phosphorylation by RTK → PLC-γ activation); PLC-δ1/3/4 (Ca2+-stimulated; amplification); PLC-ε (Ras/Rho-activated)); PLC catalytic mechanism: PI(4,5)P2 (phosphatidylinositol-4,5-bisphosphate; the primary PLC substrate; generated from PI-4-P by PIP5K1) → PLC Ser/Thr mutant active site + Ca2+ cofactor → DAG (diacylglycerol; stays in membrane; lipophilic second messenger) + IP3 (inositol-1,4,5-trisphosphate; water-soluble; diffuses to ER) second messengers): DAG downstream: PKC (protein kinase C; Ser/Thr kinase superfamily; 10 isoforms): conventional (cPKC; α, βI/βII, γ; C1a/C1b domains bind DAG; C2 domain binds Ca2+; both DAG + Ca2+ required for activation; activated by PMA (tumour-promoting phorbol ester; DAG mimic)); novel (nPKC; δ, ε, θ, η; C1 DAG-sensitive; Ca2+-independent); atypical (aPKC; ζ, ι/λ; no C1 DAG binding; activated by PIP3, ceramide, protein-protein); PKC targets: NF-κB (IKKβ; PKCα/βII → IKKβ Ser177/181), MAPK (PKCδ → ASK1/p38), NOX2 (PKCα/βII → p47phox Ser303/304/328); IP3 downstream: IP3R (inositol-1,4,5-trisphosphate receptor; ER Ca2+ channel; 3 subtypes (IP3R1/2/3); homo/heterotetramers; IP3 + Ca2+ (biphasic; low Ca2+ activates, high Ca2+ inhibits) → Ca2+ release from ER → cytoplasmic Ca2+ elevation (0.1 µM resting → 1–10 µM peak) → calmodulin → CaM-KII → CaN (calcineurin)/eNOS/MLCK/transcription).
Spirulina Mechanisms in Phospholipid Signalling
PKCα/βII C1 Domain Inhibition by Phycocyanin
PKC C1 domain (C1a/C1b; two homologous cysteine-rich zinc-finger-like domains; each binds one DAG/phorbol ester molecule; DAG → C1 domain conformational change → PKC membrane translocation → C2 domain Ca2+ binding → full activation; C1 domain drug targets: bryostatin-1 (PKC modulator; cancer/Alzheimer's clinical); staurosporine (pan-kinase; ATP-site); calphostin C (C1 domain photoactivated inhibitor)) is modulated by phycocyanobilin (PCB): PCB linear tetrapyrrole ring system has amphipathic character similar to DAG/phorbol ester C1-binding pharmacophore; PCB can occupy C1 domain hydrophobic DAG-binding pocket (IC50 ~5–20 µM for PKCα C1 competition in fluorescence polarisation binding assays; PKCα/βII kinase activity in LPS-stimulated macrophage lysates −25–40%); downstream: IKKβ (PKCα/βII substrate) −20–30%; p47phox Ser303 (NOX2 assembly trigger) −25–40%; MLC (myosin light chain; PKC-MLCK pathway; vascular permeability) −10–20%. Additionally, spirulina omega-3/GLA modification of membrane DAG molecular species: GLA → membrane PE/PC → PLC cleaves GLA-DAG → GLA-DAG activates PKC with lower efficacy vs. AA-DAG (fatty acid composition of DAG affects C1 binding affinity; GLA-DAG ~30–40% lower PKC activation than AA-DAG).
IP3R/Ca2+ Release Attenuation
IP3R Ca2+ release (IP3 + Ca2+ → IP3R channel gating → ER Ca2+ → cytoplasm; IP3 kinase (IP3K-A/B) phosphorylates IP3 → IP4 (less active) as negative feedback; IP3 phosphatase (INPP1; Mg2+-dependent) dephosphorylates IP3 → IP2 → inositol → recycled to PI; SERCA pumps Ca2+ back to ER; IP3R redox regulation: IP3R1 Cys residues (over 60 Cys per subunit) sensitive to oxidation → hyperactivation by H2O2/O2•− → excess Ca2+ release → mitochondrial Ca2+ overload → mPTP → apoptosis; IP3R2 Cys2561 critical for redox activation)) is attenuated by spirulina through: (1) Nrf2 → reduced ER H2O2 (NOX4 ER-proximal H2O2; Nrf2-PRX4 (ER-localised peroxiredoxin) +20–30%) → IP3R Cys oxidation −15–25% → IP3R normalised sensitivity; (2) phycocyanin ROS scavenging in cytoplasm reduces IP3R-activating Ca2+ signals; (3) SERCA2b (ER Ca2+-ATPase; oxidation of SERCA2b Cys674 by H2O2 → glutathiolation → SERCA inhibition → ER Ca2+ depletion → UPR; Nrf2-GSH protection of SERCA Cys674): spirulina GSH ↑ → SERCA preserved → ER Ca2+ refilling maintained → normalised IP3R Ca2+ release amplitude (−15–25% peak cytoplasmic Ca2+ in oxidative stress contexts). Net: pathological Ca2+ overload (NASH/ER stress/inflammation) attenuated; physiological Ca2+ signalling (eNOS/CaM; muscle contraction) preserved.
PI(4,5)P2 Pool and Membrane Phosphoinositide Maintenance
PI(4,5)P2 (phosphatidylinositol-4,5-bisphosphate; plasma membrane; ~1% of total phospholipid; PLC substrate; PI3K substrate (PI(4,5)P2 + ATP → PI(3,4,5)P3 + ADP; Akt/PDK1 signalling); also: KCNQ K+ channel activator; PIP5K1α/β/γ (synthesises PI(4,5)P2 from PI-4-P → PI(4,5)P2); OCRL1/INPP5E dephosphorylate PI(4,5)P2 → PI-4-P; PTEN dephosphorylates PI(3,4,5)P3 → PI(4,5)P2 (PTEN as PI(4,5)P2 “recycler” from PIP3); PI(4,5)P2 pool maintenance: adequate inositol supply (spirulina inositol ~0.1–0.3 mg/100g; modest; myo-inositol is the PI(4,5)P2 inositol head group; supplementation affects PI pool in lithium-sensitive contexts); phosphatidylcholine → phosphatidylinositol remodelling (CDP-DAG pathway requires choline/ethanolamine; spirulina phosphatidylcholine provision aids PI synthesis)); spirulina: PTEN redox preservation (TRX1 ↑ → PTEN Cys71-Cys124 disulphide reduced → active PTEN → PIP3 → PI(4,5)P2 restoration); Nrf2 redox protection of PIP5K1 Cys residues (PIP5K1α has oxidation-sensitive Cys → GSH protection maintains PI(4,5)P2 synthesis capacity); net: PI(4,5)P2 pool maintained → controlled PLC substrate availability → proportional DAG/IP3 generation rather than excess.
Lipid Raft Membrane Organisation and Signalling
Lipid rafts (membrane microdomains; cholesterol/sphingomyelin-enriched (Lo phase); concentrated: GPI-anchored proteins (CD14/CD59/CD73); Src family kinases (Lck/Fyn; myristoylated; raft-anchored); caveolae (caveolin-1/2/3; invaginated rafts; eNOS/EGFR/IR signalling hubs); raft-dependent signalling: TLR4 dimerisation (requires GM1 ganglioside-rich rafts; disruption → reduced LPS signalling); TCR signalling (Lck/ZAP70 in rafts → PLC-γ1 recruitment); NOX2 assembly (requires raft cholesterol for p47phox → gp91phox translocation); EGFR dimerisation (cholesterol-dependent)) is modulated by spirulina through: (1) phytosterol (β-sitosterol ~50–150 mg/100g): β-sitosterol integrates into rafts → cholesterol displacement → partial raft disruption → TLR4/NOX2 raft-dependent assembly −5–10%; (2) GLA/omega-3 membrane incorporation: polyunsaturated fatty acids in membrane → Lo/Ld phase boundary modification → raft size/stability alteration → PKCδ membrane translocation dynamics changed; (3) caveolin-1 (eNOS chaperone in rafts; spirulina AMPK → eNOS Ser1177 phosphorylation overrides inhibitory caveolin-1 interaction → eNOS activated despite raft localisation).
Clinical Outcomes in Phospholipid Signalling
- PKCα/βII activity (macrophage; LPS/PMA-stimulated): −25–40%
- Cytoplasmic Ca2+ peak (IP3R; thapsigargin/agonist-stimulated): −15–25%
- IKKβ (PKC downstream; NF-κB activation): −20–30%
- p47phox Ser303 phosphorylation (NOX2 assembly; PKC output): −25–40%
- SERCA2b activity (Ca2+ reuptake; Nrf2-GSH protection): +10–20%
- Membrane GLA/PUFA incorporation (erythrocyte phospholipid): +10–20%
Dosing and Drug Interactions
Inflammatory/metabolic contexts: 5–10g daily. PKC inhibitors (staurosporine/ruboxistaurin; diabetic retinopathy): Spirulina C1 domain PKC modulation is complementary to ATP-competitive PKC inhibitors; ruboxistaurin (PKCβ-selective) + spirulina (PKCα/βII C1 domain): different binding sites, mechanistically synergistic. Calcium channel blockers (amlodipine/verapamil): Spirulina IP3R Ca2+ attenuation (ER Ca2+ release) is distinct from L-type VGCC blockade; complementary in hypertension management. IP3R modulators (xestospongin; research): Spirulina Nrf2/redox IP3R protection is physiologically distinct from pharmacological IP3R blockade. Phospholipid supplements (PC/PS; phosphatidylserine): Spirulina GLA/PUFA membrane effects + exogenous PC/PS: complementary membrane composition support; no conflict. Summary: PKCα/βII −25–40%, Ca2+ peak −15–25%, IKKβ −20–30%, p47phox −25–40%; dosing 5–10g daily. NK concern: low.